UDIs & EHRS -- the ins & outs of medical device data

March 2016
Healthcare Purchasing News;Mar2016, Vol. 40 Issue 3, p6
Trade Publication
The article reports the issuance by the U.S. Food and Drug Administration (FDA) of its Unique Device Identification (UDI) rule and Meaningful Use regulations as of March 2016 to increase visibility on the use and performance of implantable devices. Also cited are the benefits of UDI like better supply chain efficiencies, as well as the scheduled event wherein experts like Ben Moscovitch of The Pew Charitable Trusts will discuss the new rules.


Related Articles

  • The FDA Compliance Program Guidance for GLPs: General. Kuwahara, Steven S. // Journal of GXP Compliance;Spring2012, Vol. 16 Issue 2, p51 

    This article provides an overview of the US Food and Drug Administration's good laboratory practice guidelines found in the compliance program guidance manuals.

  • Criminal charges not necessarily criminalization of medication error. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;4/15/2012, Vol. 69 Issue 8, p633 

    The article reports criminal charges against ApothéCure Inc., Texas pharmacy, as a result of a lethal error in making injectable colchicines leading to deaths in Oregon and Washington. It reports the revision of an eight-month-old position statement opposing criminalization of errors in...

  • Know your UDI: FDA regulation hits home for patients. Conway, Karen // Healthcare Purchasing News;Mar2015, Vol. 39 Issue 3, p58 

    The article highlights a roadmap published by the Engelberg Center for Health Care Reform (ECHCR) for effective implementation of unique device identification (UDI). Topics covered include the issues related to how hospitals and healthcare providers can utilize the UDIs placed by manufacturers...

  • Edwards snared by FDA warning letter. McCARTY, MARK // Medical Device Daily;5/31/2013, Vol. 17 Issue 105, p7 

    The article reports that Edwards Lifesciences was given a warning letter from the U.S. Food and Drug Administration on the usage of the quality systems on its plant in Draper, Utah, where cannulae and cardioplegia catheters were manufactured.

  • FDA snares fibrillator maker a second time. McCARTY, MARK // Medical Device Daily;8/16/2013, Vol. 17 Issue 158, p9 

    The article reports about the July 31, 2013 warning letter issued by the Food and Drug Administration (FDA) to Peter Schiff Enterprises for failing to perform routine quality audits since the previous inspection, a finding already observed in six prior visits.

  • BRIEFLY NOTED.  // Medical Device Daily;12/27/2013, Vol. 17 Issue 248, p3 

    The article reports on the additional input received by American medical equipment manufacturer Invacare Corp. from the third-party expert certification audit relating to the quality systems at its corporate and Taylor Street manufacturing facilities in Elyria, Ohio. The feedback indicates some...

  • Reader Q&A.  // Journal of GXP Compliance;Winter2012, Vol. 16 Issue 1, p8 

    The article presents questions and answers related to compliance issues that are challenging firms or industries in the U.S., including the difference between pooled samples and composited samples and the possibility of a 483 inspection by the Food and Drug Administration.

  • Application of the GLP Regulations: Lessons from Warning Letters II: Responsibilities of Test Facilities and Contract Testing Laboratories. Kuwahara, Steven S. // Journal of GXP Compliance;Aug2013, Vol. 17 Issue 3, p1 

    The article discusses study sponsors avoiding the cost of complete studies and contract testing laboratories wanting to accommodate the wishes of client as an area of good laboratory practices (GLP) that can create a situation where circumvention of intent of regulations becomes tempting. It...

  • Taking Preventive Action-- The Importance of Good Questions. Markovitz, David // Journal of GXP Compliance;Autumn2011, Vol. 15 Issue 4, p47 

    The article emphasizes the importance of asking good questions when taking corrective action and preventive action (CAPA) to avoid being cited by the U.S. Food and Drug Administration (FDA). Questions which can be answered by a yes or a no are characterized as inadequate and do not help...

  • Meridian whiffs on response to 483.  // Medical Device Daily;7/19/2013, Vol. 17 Issue 138, p6 

    The article reports on the warning letter issued by the U.S. Food and Drug Administration (FDA) to Meridian Medical Systems for insufficiency of details as to how the company plans to correct the listed deficiencies to the inspection findings such as the design history file (DHF) for Meridian DR...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics